Table 1 PFS and dosage by pazopanib combinations in the Pazo + study.

From: Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors

Drug combined with pazopanib

Number of patients

Median PFS

Dosage of experimental agent + dosage of pazopanib (# of pts)

Vorinostat

22

8.4 weeks

100 mg daily (n = 3)

200 mg daily (n = 9)

300 mg daily (n = 9)

400 mg daily (n = 1)

Trametinib

13

13.7 weeks

2 mg + 800 mg daily (n = 10)

2 mg + 600 mg daily (n = 2)

1 mg + 800 mg daily (n = 1)

Everolimus

6

9.9 weeks

5 mg + 400 mg daily (n = 2)

7.5 mg + 400 mg daily (n = 2)

10 mg + 600 mg daily (n = 2)

Lapatinib

2

12.0 weeks

750 mg daily + 400 mg every other day (n = 2)

Trastuzumab

1

18.0 weeks

Loading dose 4 mg/kg followed by maintenance dose 2 mg/kg + 400 mg daily (n = 1)

Back to article page